In this context, Hu et al. constructed PD-1- Meso (Mesothelin) CAR T-cells using CRISPR-Cas9 to apply against TNBC, one of the most malign types of breast cancer resistant to hormonal therapy or therapies dealing with HER2 protein receptors. The gene discussed is PDCD1; the disease is breast carcinoma.